Fabrice Barlesi

Fabrice Barlesi

Villejuif, 94805, France

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 434 publications

Bridging evidence and practice: international multidisciplinary consensus on non-metastatic NSCLC.

Bridging evidence and practice: international multidisciplinary consensus on non-metastatic NSCLC.

Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer

Published: May 26, 2026

Therapeutic targeting of RAS-mediated resistance in oncogene-driven lung cancer.

Therapeutic targeting of RAS-mediated resistance in oncogene-driven lung cancer.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: May 24, 2026

The evolving landscape of early-phase oncology: Toward more precise drug development.

The evolving landscape of early-phase oncology: Toward more precise drug development.

Journal: European journal of cancer (Oxford, England : 1990)

Published: May 01, 2026

Outcomes and Treatments of Patients With Non-Small Cell Lung Cancer Who Received Pembrolizumab.

Outcomes and Treatments of Patients With Non-Small Cell Lung Cancer Who Received Pembrolizumab.

Journal: JAMA oncology

Published: April 09, 2026

Patient-reported outcomes with adagrasib in KRYSTAL-12.

Patient-reported outcomes with adagrasib in KRYSTAL-12.

Journal: Lancet (London, England)

Published: March 13, 2026

Circulating epigenetic and epitranscriptomic biomarkers identify EGFR status, predict TKI response and reveal therapeutic vulnerabilities in NSCLC.

Circulating epigenetic and epitranscriptomic biomarkers identify EGFR status, predict TKI response and reveal therapeutic vulnerabilities in NSCLC.

Journal: Scientific reports

Published: March 09, 2026

Clinical utility of comprehensive genomic profiling: From evidence generation to sustainable access.

Clinical utility of comprehensive genomic profiling: From evidence generation to sustainable access.

Journal: European journal of cancer (Oxford, England : 1990)

Published: March 07, 2026

A plasma proteomic signature of cancer-related sarcopenia implicates the IGFBP axis in muscle dysfunction.

A plasma proteomic signature of cancer-related sarcopenia implicates the IGFBP axis in muscle dysfunction.

Journal: Molecular cancer

Published: February 15, 2026

MTAP Loss Is Frequent in Oncogene-Driven NSCLC and May Confer Sensitivity to Combined PRMT5 Inhibitors and Targeted Therapies.

MTAP Loss Is Frequent in Oncogene-Driven NSCLC and May Confer Sensitivity to Combined PRMT5 Inhibitors and Targeted Therapies.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: February 02, 2026

MTAP loss is frequent in oncogene-driven NSCLC and may confer sensitivity to combined PRMT5 inhibitors and targeted therapies.

MTAP loss is frequent in oncogene-driven NSCLC and may confer sensitivity to combined PRMT5 inhibitors and targeted therapies.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: February 02, 2026

First-line treatment patterns and real-world outcomes in patients with advanced KRAS-mutated non-small cell lung cancer with high unmet need.

First-line treatment patterns and real-world outcomes in patients with advanced KRAS-mutated non-small cell lung cancer with high unmet need.

Journal: Lung cancer (Amsterdam, Netherlands)

Published: February 01, 2026

Disease characteristics and treatment outcomes in patients with resected early-stage ALK-positive non-small cell lung cancer from the randomized ALINA trial.

Disease characteristics and treatment outcomes in patients with resected early-stage ALK-positive non-small cell lung cancer from the randomized ALINA trial.

Journal: Lung cancer (Amsterdam, Netherlands)

Published: January 16, 2026

Showing 1-12 of 434

Last Updated: 09/26/2026